cT84.66
cT84.66 is a highly efficient tumor-targeting agent against carcinoembryonic antigen (CEA). cT84.66 engages in bivalent binding with CEA via variable region antigen-binding sites, enabling precise targeting of CEA-producing tumor cells for delivery of therapeutic radiation. cT84.66 exhibits high tumor uptake rate, rapid clearance rate, and excellent tumor-to-blood ratio. With dual functions as an imaging agent and an antibody-directed radiotherapy agent, cT84.66 is widely used in studies of colorectal cancer and metastatic CEA-positive malignancies.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
All Radionuclide-Drug Conjugates (RDCs) Isoforms
More
Biological Activity
Human IgG1 kappa
Human
cT84.66 binds bivalently and with high affinity (Ka=4.0 × 1010 M-1) to CEA[1].
cT84.66 (5-10 mCi 123I per 1 mg cT84.66 minibody) can be efficiently radiolabeled with 123I, yielding a product with ≥95% immunoreactivity, ≥90% radiolabeling efficiency, and endotoxin levels <1 unit/mL[1].
cT84.66-DOTA has superior kinetic stability to cT84.66-DTPA when labeled with 111In or 90Y[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
90Y-DOTA-cT84.66 achieves high tumor uptake (approaching 60% ID/g) with low bone uptake (1%-2% ID/g) in tumor-bearing mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
CEACAM5/CEA/CD66e
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
[1]. Wong JY, et al. Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin Cancer Res. 2004;10(15):5014-5021. [Content Brief]
[2]. Wong JY, et al. A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies. Cancer Biother Radiopharm. 2006;21(2):88-100. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
cT84.66 Related Classifications
HY-P992339 Related Classifications
Powered by Bioz
- cT84.66
- Radionuclide-Drug Conjugates (RDCs)
- CEA-producing tumor cells
- CEA
- colorectal cancer
- tumor-bearing mice
- antibody-guided radiation therapy
- human antichimeric antibody responses
- LS-174T colon cancer xenografts
- metastatic CEA-producing malignancies
- hematologic toxicity
- carcinoembryonic antigen
- Inhibitor
- inhibitor
- inhibit